Rituximab in Treating Patients With Hodgkin's Lymphoma
Trial ID or NCT#
Status
Purpose
Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.
Official Title
Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Sarah Daadi
6507256456
View on ClinicalTrials.gov